A Phase I Clinical Trial of CpG Oligonucleotide 7909 (PF-03512676) in Patients with Previously Treated Chronic Lymphocytic Leukemia

CpG oligonucleotide 7909 (CpG 7909, PF-03512676), a synthetic 24mer single stranded agonist of TLR9 expressed by B cells and plasmacytoid dendritic cells, is immunomodulatory and can cause activation-induced death of chronic lymphocytic leukemia (CLL) cells. We report a phase I study of CpG 7909 in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zent, Clive S., Smith, Brian J., Ballas, Zuhair K., Wooldridge, James E., Link, Brian K., Call, Timothy G., Shanafelt, Tait D., Bowen, Deborah A., Kay, Neil E., Witzig, Thomas E., Weiner, George J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3438221/
https://ncbi.nlm.nih.gov/pubmed/21812536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2011.608451
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados